Vaccine Schedule

The UK childhood immunisation schedule administered by the NHS in 2025 includes seventeen routine doses by age fourteen: six-in-one at eight, twelve and sixteen weeks, rotavirus at eight and twelve weeks, meningitis B at eight, sixteen and twelve months, PCV at twelve weeks and twelve months, MenC at twelve months, MMR and varicella at twelve and three to four years, diphtheria-tetanus-pertussis at three to four years, and HPV at twelve to thirteen years. The schedule has expanded substantially since the 1980s.

The US Centers for Disease Control schedule for the same age range included eleven doses in 1983 and seventy two by 2024. The UK schedule is less expansive than the US but has grown in parallel. Pre-licensure trial durations, comparator choice and long-term safety follow-up methodologies vary considerably between products and between jurisdictions. In the United States, the National Childhood Vaccine Injury Act of 1986 removed manufacturer liability for vaccine-related injuries, funding compensation instead through a levy on each dose sold.

The US National Childhood Vaccine Injury Act of 1986 removed manufacturers' civil liability for vaccine injuries and created the Vaccine Injury Compensation Program in its place. Since 1988, the VICP has paid approximately $5.1 billion in compensation for around 11,000 adjudicated claims. Compensated injuries include febrile seizures, shoulder injuries related to vaccine administration, encephalopathy, anaphylaxis and intussusception. The fund is financed by a $0.75 excise tax per disease covered by each dose sold.

The programme maintains a Vaccine Injury Table listing specific conditions presumed caused by specific vaccines when they occur within defined time windows. Over 27,000 petitions have been filed since inception. The design was explicit: remove manufacturer liability to maintain vaccine supply stability, redirect compensation through a federal no-fault mechanism. The UK equivalent is the Vaccine Damage Payment, a capped flat payment of £120,000 per accepted claim, available since 1979 for cases of at least sixty percent disability.

MMR first dose coverage in England fell to 85.1% in 2023/24 for children aged two, the lowest level in fifteen years. Second dose coverage for children aged five was 73.7%. The WHO target for measles elimination is ninety five percent first dose and ninety five percent second dose coverage. A first dose coverage of 85.1% leaves approximately one in seven children unprotected, creating conditions for measles outbreaks even when most individuals are vaccinated.

Coverage has declined steadily from a peak of 92.3% in 2012/13. The decline predates the COVID-19 pandemic but accelerated during it. Measles outbreaks occurred in West Midlands and London in 2023/24, with 2,911 confirmed cases, the largest outbreak in England since 1994. UKHSA attributed the resurgence directly to coverage gaps. The policy response has focused on catch-up campaigns rather than addressing the structural and trust-related factors driving the decline.

The US CDC childhood immunisation schedule recommends seventy-two doses of sixteen vaccines between birth and age eighteen as of 2024, compared with twenty-four doses of seven vaccines in 1983. The UK schedule recommends approximately thirty-two doses of twelve vaccines in the same age range. Each individual vaccine was tested in isolation during its licensure trial, typically against another vaccine or aluminium-containing placebo rather than an inert saline placebo. No randomised controlled trial has ever tested the combined schedule as administered.

This is because combined schedule testing would require a control group of unvaccinated children, which is considered ethically impermissible under current guidelines. The Institute of Medicine (now National Academy of Medicine) acknowledged in its 2013 report "The Childhood Immunization Schedule and Safety" that the "key elements of the schedule, the number, frequency, timing, order and age at administration of vaccines, have not been systematically examined in research studies." The report recommended research into the cumulative biological effects of the schedule but no such studies have been completed.

The schedule expanded most rapidly after the 1986 NCVIA removed manufacturer liability, with the number of recommended doses approximately tripling between 1986 and 2024. The Vaccine Safety Datalink (VSD), a CDC-managed database of nine US health maintenance organisations, monitors post-market safety signals but does not constitute a controlled trial of the combined schedule. The gap between individual vaccine testing and combined schedule safety assessment remains the most significant evidence gap in paediatric immunisation policy.

The US National Childhood Vaccine Injury Act (NCVIA) of 1986 removed product liability from vaccine manufacturers, creating a no-fault compensation system (the Vaccine Injury Compensation Program, VICP) funded by a $0.75 excise tax per dose. The Act was passed after multiple lawsuits in the 1980s threatened to drive manufacturers out of the market. Since 1988, the VICP has paid over $4.7 billion in compensation across approximately 9,600 claims. Manufacturers cannot be sued in civil court for design defect, failure to warn or manufacturing defect related to vaccines covered by the programme.

This is because the economics of vaccine litigation created a perverse incentive. In a normal product liability regime, the threat of lawsuits incentivises manufacturers to invest in safety monitoring and product improvement. The 1986 Act removed this incentive entirely. Bruesewitz v. Wyeth (2011, US Supreme Court, 6-2) confirmed that NCVIA preempts all state-law design defect claims against vaccine manufacturers, even when a safer alternative design exists. No other pharmaceutical product category in the United States has comparable blanket liability protection.

The United Kingdom operates a separate scheme: the Vaccine Damage Payment Act 1979 provides a one-off payment of £120,000 to individuals disabled by a vaccine, with a threshold of 60 per cent disability. Between 1979 and 2023, approximately 950 awards have been made. Both the US and UK systems place the burden of proof and the financial cost on the injured individual or the taxpayer, not on the manufacturer. The UK scheme has not been updated since 2007 and remains one of the least generous compensation programmes in Europe.

Hazell and Shakir's 2006 systematic review in Drug Safety analysed thirty-seven studies from twelve countries and concluded that the median underreporting rate for spontaneous adverse drug reaction reporting systems was 94 per cent, meaning approximately 6 per cent of events were reported. The UK Yellow Card scheme, operated by the MHRA, showed reporting rates between 6 and 10 per cent depending on the severity of the reaction. Serious reactions were more likely to be reported than mild ones, but even fatal adverse reactions were underreported by approximately 50 per cent.

This is because spontaneous reporting systems rely on healthcare professionals and patients voluntarily submitting reports, a process that requires recognition that the event may be drug-related, knowledge that the reporting system exists and willingness to complete the paperwork. The system was not designed to capture all events but to detect safety signals for further investigation. However, public-facing statements about vaccine safety frequently cite the absolute number of Yellow Card reports as if they represent the total burden of adverse events.

The MHRA received approximately 470,000 Yellow Card reports for COVID-19 vaccines through 2023, a reporting rate likely elevated by the mass vaccination programme and heightened public awareness. For routine childhood vaccines, reporting rates revert to the baseline 6 to 10 per cent. The denominator problem is fundamental: if only one in ten adverse events is reported, the true burden of adverse events is approximately ten times the reported figure. This does not mean all reported events are caused by vaccines, but the underreporting rate means the raw Yellow Card data systematically understate the total number of temporally associated adverse events.

The UK immunisation schedule (Green Book, UKHSA 2024) administers vaccines at 8, 12 and 16 weeks, 12 months and 18 months. By 18 months of age, a child following the full schedule receives a cumulative aluminium adjuvant dose of approximately 4,925 μg from the 6-in-1, PCV13 and MenB vaccines. Aluminium salts (aluminium hydroxide, aluminium phosphate) are used as adjuvants to amplify the immune response. The FDA parenteral daily dose limit for aluminium in intravenous feeding solutions is 25 μg per day (4-5 μg/kg) based on demonstrated neurotoxicity at higher loads.

This is because aluminium adjuvants work by creating a local inflammatory depot at the injection site that recruits and activates antigen-presenting cells. However, Flarend et al. (1997, Vaccine) demonstrated using radiolabelled aluminium that approximately 17% of intramuscularly injected aluminium adjuvant is absorbed into the systemic circulation within 28 days. Mold et al. (2018, Journal of Trace Elements in Medicine and Biology) found elevated aluminium concentrations in brain tissue samples from individuals with autism spectrum disorder. Khan et al. (2013, BMC Medicine) demonstrated that fluorescently labelled aluminium particles injected intramuscularly in mice migrated to distant organs including the brain.

The safety testing of aluminium adjuvants has never used an inert saline placebo. Vaccine safety trials use either another aluminium-containing vaccine or a solution of aluminium adjuvant alone as the "control," making it impossible to distinguish adjuvant-related adverse effects from vaccine-specific effects. Exley (2020, Journal of Inorganic Biochemistry) argued that the accumulated body of evidence on aluminium neurotoxicity warrants an immediate moratorium on aluminium adjuvants pending proper safety evaluation with true inert controls.

The 1962 US childhood immunisation schedule contained 5 vaccine doses by age five. By 1986, when the National Childhood Vaccine Injury Act removed manufacturer liability, the schedule had expanded to 24 doses by age 18. The 2024 CDC schedule contains 72 doses of 16 vaccines from birth to age 18, including hepatitis B within 24 hours of birth.

This is because each addition follows an individual risk-benefit analysis, but the cumulative immunological load has never been tested as a combined intervention. The Institute of Medicine (2013) stated that no studies have compared health outcomes between entirely unvaccinated and fully vaccinated children, and recommended research into the full schedule.

Between 1986 and 2024, recommended doses tripled. Each new vaccine represents a guaranteed market under the Vaccines for Children programme. Manufacturers bear no liability under the 1986 Act. The financial incentive structure rewards schedule expansion with zero litigation risk.

Aluminium oxyhydroxide is the most widely used vaccine adjuvant globally, present in DTaP, hepatitis B, HPV and pneumococcal vaccines among others.

This is because aluminium salts create a depot effect at the injection site, prolonging antigen exposure to immune cells. Research by Gherardi et al. at Créteil demonstrated that aluminium particles can persist at the injection site for years and translocate to distant organs including the brain in animal models.

This leads to ongoing scientific debate. Proponents emphasise aluminium adjuvants' seven-decade safety record and the tiny doses involved. Critics point to the cumulative schedule: by age two, a child following the UK immunisation schedule receives approximately 3.7 mg of aluminium across multiple doses, and the pharmacokinetics of injected versus ingested aluminium differ substantially.

Individual vaccines are licensed following phase three trials evaluating each product in relative isolation. No randomised controlled trial has evaluated the cumulative childhood immunisation schedule as a complete programme, testing multiple simultaneous vaccines administered across the entire schedule. The US Institute of Medicine noted in its 2013 review "The Childhood Immunization Schedule and Safety" that the schedule had not been studied in its entirety and called for research into the combined schedule as administered.

UK infants at the eight-week visit receive the six-in-one vaccine, rotavirus drops and MenB simultaneously. The immunological interaction of multiple simultaneous antigens and adjuvants is not evaluated in licensing trials. The 2013 IOM report stated explicitly that the committee could not rule out long-term health effects of the schedule because the relevant studies had not been conducted. The IOM did not conclude the schedule causes harm; it concluded the question has not been formally tested.

The US Centers for Disease Control childhood immunisation schedule recommended 24 doses of 7 vaccines by age 18 in 1983. By 2024, the schedule recommends 72 doses of 16 vaccines by age 18. The UK schedule expanded from 8 doses at age 2 in 1990 to 20 doses at age 2 in 2024. No long-term randomised trial has ever compared fully vaccinated children against fully unvaccinated children for overall health outcomes.

This is because each vaccine is tested individually against either a different vaccine or an aluminium-adjuvant placebo, not against a true inert saline placebo. The combined schedule, in which an infant may receive 6 antigens in a single visit, has never been tested as a combined immunological intervention. The Institute of Medicine (now National Academy of Medicine) acknowledged in its 2013 report that "the committee could not determine whether the number of antigens in the childhood immunisation schedule was associated with increased risk for autoimmune disease."

The 1986 National Childhood Vaccine Injury Act removed product liability from vaccine manufacturers in the United States. Since that date, the schedule expanded from 24 to 72 doses. The Vaccine Injury Compensation Program has paid out over $4.8 billion in claims since inception. Manufacturers face no civil liability for design defects, removing the standard market incentive to minimise adverse effects.

A longitudinal study following individuals who survived natural measles infection found detectable neutralising antibodies persisting for at least 65 years, with estimated half-lives suggesting lifelong immunity.

This is because natural infection exposes the immune system to the complete pathogen, triggering robust mucosal, cellular and humoral responses simultaneously. Vaccination typically stimulates a more narrow antibody response that wanes faster: two-dose MMR provides approximately 96% protection initially, declining measurably after 15 to 20 years.

This leads to the phenomenon of waning vaccine-derived immunity in highly vaccinated populations. Outbreaks among vaccinated adults are increasingly documented, requiring booster programmes that were not part of the original vaccination rationale.